Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

This study has been completed.
Novo Nordisk A/S
Information provided by (Responsible Party):
Ildiko Lingvay, University of Texas Southwestern Medical Center Identifier:
First received: January 4, 2012
Last updated: June 23, 2016
Last verified: June 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2016
  Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)